Merrimack Pharmaceuticals (MACK) : During the past 4 weeks, traders have been relatively bearish on Merrimack Pharmaceuticals (MACK), hence the stock is down -18.1% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4% relative to the S&P 500. The 4-week change in the price of the stock is -18.28% and the stock has fallen -4.63% in the past 1 week.
For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 10.39% and the fifty day Moving Average is 13.86%. Merrimack Pharmaceuticals, Inc. has dropped 24.88% during the last three month period . Year-to-Date the stock performance stands at -40%.
Merrimack Pharmaceuticals (MACK) : 2 investment research analysts covering Merrimack Pharmaceuticals (MACK) have an average price target of $10 for the near short term. The highest target price given by the Brokerage Firm to the stock is $13 and the lowest target is $7 for the short term. Analysts expect the variance to be within $4.24 of the average price.
Merrimack Pharmaceuticals (NASDAQ:MACK): On Fridays trading session , Opening price of the stock was $4.74 with an intraday high of $4.88. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $4.62. However, the stock managed to close at $4.74, a loss of 0.63% for the day. On the previous day, the stock had closed at $4.77. The total traded volume of the day was 2,168,640 shares.
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has six targeted therapeutic oncology candidates in clinical development (MM-398, MM-302, MM-121, MM-111, MM-151 and MM-141). The Companys most advanced program is its investigational agent MM-398. The Company also has multiple product candidates in preclinical development and a discovery effort advancing additional candidate medicines. The Company has an agreement to utilize its manufacturing know-how to develop, manufacture and exclusively supply bulk drug to a third party, who processes the drug into a finished product and commercializes it globally. The Company is also developing in vitro and in vivo companion diagnostics for use with each of its oncology therapeutic product candidates.